BIOCRYST PHARMACEUTICALS INC 10-Q filing
Filed 2026-05-06 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001628280-26-031238
- Form type
- 10-Q
- CIK
- 0000882796
- Primary document
- https://www.sec.gov/Archives/edgar/data/882796/000162828026031238/bcrx-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for BIOCRYST PHARMACEUTICALS INC.
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Cost Of Revenue | $5.4M | - | - |
| Operating Income | $-701.6M | - | - |
| Net Income | $-721.8M | - | - |
| Eps Basic | -2.98 | - | - |
| Eps Diluted | -2.98 | - | - |
| Cash And Equivalents | $171.6M | - | - |
| Total Assets | $465.1M | - | - |
| Total Liabilities | $1.0B | - | - |
| Shareholders Equity | $-553.8M | - | - |
| Operating Cash Flow | $-61.8M | - | - |